Abbott Laboratories ABT

Reference table

1. What the business is, and the acquisition that changed it

Chief executive Robert Ford; 115,000 employees; NYSE-listed; CIK 0000001800; reporting in USD.

Four reportable segments, and seg_prod ties. The four fiscal-2025 lines sum to $44,311M against reported revenue of $44,328M — a 0.04% residual. Verified clean.

Read the last column and the whole strategic story is there. Total revenue is essentially flat over three years, because Medical Devices added $6.7 billion and Diagnostics lost $7.6 billion. The COVID-testing runoff consumed the entire device franchise's growth. That is the problem Abbott has just spent $20.6 billion solving.

The acquisition, from the 10-Q, verbatim:

> "On March 23, 2026, Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion. The acquisition was funded primarily through the issuance of $20.0 billion of long-term debt in March 2026, with the remainder funded by cash on hand. Under the terms of the agreement, Abbott paid $105 per common share in cash. As part of the acquisition, Abbott assumed approximately $2.8 billion of Exact Sciences' debt, nearly all of which was repaid as of June 30, 2026. The acquisition of Exact Sciences has established Abbott's position in the cancer diagnostics market and expands its portfolio to include products such as Cologuard®, Oncotype DX® and Cancerguard."

> "Following the acquisition, the sales of Exact Sciences are presented as Cancer Diagnostics."

Cancer Diagnostics contributed $919 million in the June 2026 quarter (its first full quarter) and $1,015 million in the first half (roughly 3.3 months of ownership). Annualising the quarter gives approximately $3.7 billion of revenue against a $20.6 billion price — roughly 5.6x sales.

The debt, from Note 10, in full:

A weighted average coupon in the mid-4s on $20 billion is roughly $900 million a year of incremental pre-tax interest, against fiscal-2025 pre-tax income of $8.466 billion. That alone is over 10% of pre-tax earnings, and it is why GAAP EPS is falling while revenue rises.

seg_geo is corrupt and REJECTED in full. The fiscal-2025 entry contains fields literally named "C [N]", "D [E]", "I [N]", "J [P]" and "C [H]" — truncated XBRL country tags — alongside a Non-US subtotal of $15,979M and UNITED STATES of $17,126M. US plus Non-US sums to $33,105M against revenue of $44,328M: $11.2 billion, or 25% of the company, is simply unaccounted for. The bracketed fields sum to $9,883M and cannot be attributed to countries with confidence. No geographic figure from the vendor appears anywhere in this dive.

2. The June quarter — adjusted beat, GAAP halved

Three things.

First, revenue accelerated because of the acquisition, not in spite of it. Q2 2026 revenue of $12,593M includes $919M of Cancer Diagnostics. Excluding it, revenue was roughly $11,674M — +4.8% year on year, not +13.0%. Any reader treating the +13.0% as organic will materially overestimate this business.

Second, GAAP operating margin fell 420 basis points to 14.2% while gross margin actually rose (58.0% against 56.4%). The gap is acquisition-related amortisation, restructuring and integration cost below the gross line. GAAP diluted EPS of $0.53 against $1.01 is a 47% decline in a quarter with 13% revenue growth.

Third, the GAAP-to-adjusted gap is now 69% — trailing GAAP diluted EPS of $3.11 against trailing adjusted EPS of $5.26. That is the second-widest in this batch and it is widening, because $22.9 billion of newly recognised goodwill and intangibles will amortise for years. Every forward multiple in this dive uses adjusted EPS, and the trailing GAAP multiple of 33.9x is shown for completeness and not used.

A 2025 restructuring programme is disclosed: "In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostics and medical devices businesses," with asset impairment charges recognised in the first six months of 2025. The restructuring predates the acquisition and is a separate drag.

Litigation, from Note 12, unsized and material: "Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow's milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC) and inadequately warn..." There is no quantified accrual in the extracted text and no vendor field of any kind. We flag it as an unquantified contingent liability.

3. Balance sheet — the largest single correction in this batch

Correction 1 — the balance sheet predates the largest financing event in Abbott's history, and the understatement is 313%. The vendor's most recent balance sheet is 2025-12-31, showing net debt of $6,545M. Between that date and 2026-06-30, Abbott issued $20.0 billion of senior notes and closed a $20.6 billion acquisition. The vendor reports net debt of $6.545B; the 10-Q supports $27.005B; we use $27.005B. Consequential: net debt/EBITDA rises from 0.66x to 2.72x; goodwill and intangibles rise from $29.561B to $52.455B — 48.0% of total assets; and total assets rise 25.9%. This is the CRM defect class (a stale balance sheet missing the largest financing event) in its largest absolute form in this batch.

Correction 2 — the vendor's own file is internally inconsistent by roughly $21 billion, which is worth stating precisely. bal_a[0].netDebt is $6,545M. But km_ttm.enterpriseValueTTM is $210.198B against a market capitalisation of $182.694B, implying net debt plus minority interests of $27.504B — i.e. the derived enterprise value DOES reflect the acquisition financing. netDebtToEBITDATTM of 2.766x likewise implies roughly $27.5B. So two parts of the same payload disagree by $21 billion: the balance-sheet block is stale and the trailing-metric block is current. A reader screening on the balance sheet would put Abbott at 0.66x leverage; a reader screening on the ratio block would put it at 2.77x. The ratio block is right. We state this because the balance sheet is the field most readers would trust.

Correction 3 — the vendor's fiscal-2025 debt lines do not match the 10-Q's comparative column. Vendor longTermDebt $10,827M and shortTermDebt $3,309M against the filing's $9,896M and $3,033M; the vendor also carries capitalLeaseObligations of $931M, which reconciles most of the gap. Total debt: vendor $15,067M against filing $12,929M plus leases. Immaterial next to correction 1, and recorded.

The rebuilt enterprise value:

> Market cap $182.694B (1,730,384,021 shares × $105.58)

> + total debt $32.608B (10-Q, 2026-06-30)

> + noncontrolling interests $0.652B

> − cash $5.104B − short-term investments $0.499B

> = corrected enterprise value $210.351B

The vendor reports $210.198B — within 0.07%. The vendor's enterprise value is essentially correct and its balance sheet is not, and both are in the same file.

Leverage in context. Net debt of $27.005B against roughly $9.94B of trailing EBITDA is 2.72x. Interest coverage is still 12.45x on the trailing period, but that period contains only one quarter of the new coupon; on a full-year run-rate the incremental $900 million takes coverage nearer 8x. debtToEquityRatioTTM of 0.638x is computed on the stale balance sheet; on the filed figures it is 0.630x against shareholders' investment of $51,762M — coincidentally similar because equity is large. returnOnInvestedCapitalTTM of 6.07% was already low before $22.9 billion of purchase accounting was added to the denominator, and it will fall further.

There is no preferred stock: the 10-Q balance sheet states "Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued."

4. Cash flow and capital returns

Free cash flow of $7.395B in 2025 is a 16.7% margin and a 4.05% yield on today's market capitalisation — solid, and the vendor's freeCashFlowYieldTTM of 4.77% is computed on a trailing figure that includes a stronger recent period. Capital expenditure is steady at roughly $2.2 billion, or 4.9% of revenue.

The buyback has been shrinking and is now nominal: $3.795B (2022) → $1.227B → $1.295B → $893M (2025) — under half a percent of market capitalisation. Diluted shares have barely moved: 1.764B in 2022 to 1.743B in the June 2026 quarter, a 1.2% reduction in three and a half years. With net debt now at 2.72x EBITDA, the buyback is unlikely to grow.

Dividend. The vendor reports lastDividend: 2.48 and dividendPerShareTTM: 2.48, yielding 2.35%. That $2.48 is the trailing-twelve-month total. The 10-Q balance sheet carries dividends payable of $1,093M at 2026-06-30 against 1,730,384,021 shares — approximately $0.632 per share for the quarter, a $2.53 annualised run-rate and a 2.40% forward yield. Payout is 78.5% of trailing GAAP EPS and 48.1% of trailing adjusted EPS — the divergence is entirely the acquisition amortisation, and the adjusted figure is the meaningful one.

Total shareholder yield is approximately 2.9% — 2.40% dividend plus roughly 0.49% buyback. Free cash flow of $7.395B against a roughly $4.4B dividend leaves about $3 billion a year for deleveraging, which is the correct use of it.

5. Valuation — priced in or room?

At $105.58 (market cap $182.694B, corrected enterprise value $210.351B):

Note the FY2028 EPS range: $4.496 to $8.060, a 1.79x spread on 10 analysts, against FY2026's $5.475–$5.545 (a 1.3% spread on 17). The near years are essentially guided and the far year is a genuine disagreement, most of which is about whether the Exact Sciences integration works. We use the FY2027 line (17 analysts, tight) as the base anchor and FY2028 only for the tails, with coverage disclosed.

est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature and are rejected. ebitdaAvg / revenueAvg = 26.76% and ebitAvg / revenueAvg = 19.23% in all eight years, to four significant figures. These happen to be close to Abbott's actual figures (fiscal-2025 EBITDA was 26.06% of revenue and operating margin 18.2%), which makes them more dangerous rather than less — they look right and are constructed. Per the data contract, all forward valuation runs on epsAvg, which cross-checks: FY2026 epsAvg $5.515 × 1.743B shares = $9.61B against niAvg of $9.647B, a 0.4% residual.

Peer context. The vendor peer set is a healthcare grab-bag mixing devices, pharma and managed care: UnitedHealth ($370.9B), Merck ($317.3B), Novartis ($291.3B), Novo Nordisk ($196.6B) and Thermo Fisher ($209.6B) are not Abbott comparables in business model. The defensible device peers are Medtronic ($110.1B at $86.02), Stryker ($128.9B at $336.24), Boston Scientific ($73.0B at $49.11) and Intuitive Surgical ($130.0B at $367.88). Abbott at $182.7B is the largest of that group. Dexcom, the other half of the continuous-glucose-monitoring duopoly the knowledge base identifies, is not in the payload. No peer multiples are supplied, so no peer-multiple comparison is drawn. Note that GILD, also in this batch, appears in Abbott's peer set — a hepatitis and HIV franchise is not a device comparable and the two dives should not be read against each other on multiples.

5a. What today's price assumes (the inversion)

At $105.58 — 19.1x FY2026 consensus adjusted EPS and 17.4x FY2027 — the price embeds:

• Revenue reaches $50.309B in 2026 and $54.699B in 2027. (Consensus; 20 analysts each.) The FY2026 figure is +13.5%, of which the majority is the Exact Sciences consolidation — Cancer Diagnostics contributed $919M in one quarter, so roughly $3.0-3.7B of the $5.98B increase is acquired. Underlying growth is closer to 5%.
• The Exact Sciences acquisition earns its cost. (Our framing.) $20.6 billion at roughly 5.6x annualised revenue, funded entirely with debt at coupons to 5.600%. This is the most fragile assumption in the price because there is exactly one quarter of evidence, the deal closed 134 days ago, and return on invested capital was already 6.07% before it.
• Adjusted EPS reaches $6.722 by 2028 — 30.5% above the $5.152 delivered in 2025 — while GAAP EPS is currently falling. (Consensus; 10 analysts on that line, range $4.496–$8.060.) The adjusted measure excludes the acquisition amortisation that is causing the GAAP decline, so the two series will keep diverging.
• Net debt of $27.005B comes down. (Our assumption; the filing gives the debt.) Free cash flow of $7.395B less roughly $4.4B of dividend leaves about $3 billion a year. At that pace leverage returns below 2x in roughly two years, assuming no further acquisitions and no buyback.
• The market keeps paying 17-19x on the forward year. (Our number.) At 15x FY2027E the stock is $91; at 21x it is $127. Abbott has historically traded 22-26x forward, so today's 19.1x already embeds a de-rating — the question is whether it is enough of one for a company at 2.72x leverage with falling GAAP earnings.

5b. The return bridge (why the multiple moves)

Expected return over roughly two years decomposes as: adjusted EPS growth (+21.9%, from FY2026E $5.515 to FY2028E $6.722) + multiple drift (COMPRESSION, from 19.1x to 17x on the respective forward year, −11%) + shareholder yield (+2.9% a year, ~5.9% compounded) ≈ +16% to +17% total, or roughly +8% annualised.

Our base assumes mild compression, and the reason is leverage rather than growth. Abbott has historically earned a premium multiple partly because it carried almost no debt. At 2.72x EBITDA with $52.5 billion of goodwill and intangibles and a 6.07% return on invested capital that will fall further, the balance-sheet component of that premium has been spent. The growth component is intact — 10% adjusted EPS growth is unchanged from the pre-deal trajectory.

If the multiple simply HELD at 19.1x on FY2028E the price would be $128 (+21%); if it compressed to 15x the price would be $101 (−4%). The bull case at $145 is 18x the FY2028 consensus HIGH of $8.060 — lower multiple, better number — and lands exactly on the street's $145 high target. The bear case at $90 is 15x the FY2027 consensus LOW of $6.003 and sits 2.2% below the street's $92 low.

5c. Variant perception (where we differ, what would surprise)

• We differ from every screen on leverage, and the gap is $20.5 billion. The balance sheet in every standard feed shows net debt of $6.545 billion and 0.66x EBITDA; the 10-Q supports $27.005 billion and 2.72x. Abbott is a different credit than it screens as, and the change happened 134 days ago. Notably the vendor's own enterprise value and net-debt-to-EBITDA ratio DO reflect it — the file disagrees with itself by $21 billion, and the balance-sheet block is the one that is wrong.
• We differ on how to read the revenue acceleration. Consensus FY2026 revenue growth of +13.5% and the June quarter's +13.0% are both substantially acquired. Stripping the $919M of Cancer Diagnostics, June-quarter revenue grew roughly 4.8%. Watchable number: Cancer Diagnostics revenue in the 2026-10-21 print. Anything below $950M would mean the acquired business is not growing, and at 5.6x sales it has to.
• We think the GAAP/adjusted divergence is more informative than usual here. Trailing GAAP EPS of $3.11 against adjusted of $5.26 is a 69% gap, and it is widening because $22.9 billion of new goodwill and intangibles has just been added. Most of the gap is genuinely non-cash amortisation and the adjusted number is the right one for valuation. But the interest on $20 billion of new notes is entirely cash, entirely recurring, and is in BOTH measures — roughly $900 million a year, or about $0.40 a share after tax. That is 7% of the FY2027 consensus and it is permanent.
• We have essentially no independent conviction, because the knowledge base lane is 73% management voice. Eight of eleven entity claims are Abbott's own executives reciting fiscal-2020 guidance, mis-filed under another company's channel slug and six and a half years stale. After excluding them, four claims remain and two are about the continuous-glucose-monitoring category rather than the equity.
• Positive surprise that would force a re-rate: Cancer Diagnostics revenue above $1.0 billion in the September quarter with a stated margin; a 200-day-average reclaim above $108.10 on an earnings beat; net debt falling below $25 billion by year-end, which would show the deleveraging plan is real; or a resolution of the necrotizing enterocolitis litigation at a quantified and modest number.
• Negative surprise that would break the thesis: Cancer Diagnostics revenue flat or falling; a goodwill impairment against the newly recognised $11.2 billion; the necrotizing enterocolitis litigation producing a large accrual; or Medical Devices growth slowing below 8%, which would remove the only organically compounding segment. At RSI 79 into the 200-day, none of these is absorbed by the entry.

Synthos fair values

Anchors are multiples of the fiscal-2027 and fiscal-2028 consensus adjusted-EPS distributions (FY2027 mean $6.063, low $6.003, high $6.182 on 17 analysts; FY2028 mean $6.722, low $4.496, high $8.060 on 10 analysts — the wide FY2028 range is disclosed and is why it is used only for the tails).

• Bear ~$90 — 15x the FY2027 consensus LOW of $6.003. Cross-check: 16.3x FY2026E; 2.2% below the street's own $92 low target; 8.9% above the 52-week low of $82.56. The scenario: Exact Sciences underdelivers, a goodwill impairment or a litigation accrual lands, deleveraging stalls, and the multiple compresses to a mid-teens level appropriate to a 2.7x-levered mid-single-digit organic grower. −14.8%.
• Base ~$115 — 19x the FY2027 consensus MEAN of $6.063. Cross-check: 20.9x FY2026E; 17.1x FY2028E; corrected EV of $226.2B on FY2027E revenue of $54.699B is 4.14x sales. Sensitivity, stated openly: 17x FY2027E gives $103, 2.4% BELOW spot, and 21x gives $127, above the street's median. The whole answer lives in a 17-21x band. The scenario: revenue lands near consensus, Cancer Diagnostics grows, adjusted EPS compounds at 10%, net debt falls toward 2x, and the multiple drifts modestly lower to reflect the leverage. +8.9%, plus about 5.9% of compounded shareholder yield.
• Bull ~$145 — 18x the FY2028 consensus HIGH of $8.060, i.e. a lower multiple applied to a materially better number. Cross-check: 23.9x FY2027E; exactly the street's $145 high target. The scenario: Exact Sciences integrates cleanly and Cologuard penetration accelerates, Medical Devices holds low-double-digit growth on FreeStyle Libre, deleveraging restores the balance-sheet premium, and Abbott re-rates toward its historical 22-25x. +37.3%.

Base is 8.9% above spot; asymmetry roughly 2.52:1 to the upside (14.8% down, 37.3% up). That ratio is the second-best in this batch and it is the strongest argument for the name. What holds it at Watch is that the base sits below the street, the entry is at RSI 79.3 into the 200-day after a 20.8% three-month bounce, the leverage change is 134 days old with one quarter of evidence, and the knowledge-base lane is three-quarters management voice.

6. Knowledge base — eleven claims, eight of them Abbott's own management

Raw hits: 14 (11 entity, 3 text). Used: 4. Discarded: 10. Searches covered Abbott, Libre, Exact Sciences and Cologuard.

The attribution finding, and it is the second instance of the same defect in this batch.

EIGHT of the eleven entity claims are dated 2020-01-23 and all come from a single channel slug named for the chief executive of an unrelated pharmaceutical company. Their content is unmistakably Abbott's own management:

> "FY2020 guidance: 7-8% organic sales growth, adjusted EPS $3.55-$3.65 (double-digit growth), ~59% gross margin; Q1 EPS $0.69-$0.71." (conviction 60)

> "7-8% organic sales growth and double-digit EPS growth sustainable for years; broad-based across four businesses, not one driver, so law-of-big-numbers doesn't apply." (conviction 80)

> "FreeStyle Libre is global CGM market leader (~2M users, ~$2B sales, +70% YoY); mass-market consumer/pharmacy model targets millions of basal/non-insulin patients TAM." (conviction 88)

> "MitraClip (~$700M, +30%) only ~5% penetrated — multi-year, multi-billion runway; TriClip, Tendyne, Portico launches deepen best-in-class structural-heart portfolio." (conviction 82)

Plus four more on Alinity, Established Pharmaceuticals, acquisition strategy and nutrition guidance.

No independent analyst issues per-share guidance ranges for a company's next quarter. These are the company's own executives. They are excluded from the conviction pool entirely, quoted here at half weight, and they are additionally six and a half years stale — the fiscal-2020 guidance they contain has long since been superseded.

The same channel slug carries IBM's chief executive in this batch. That makes it a systemic mis-filing rather than a single error, and it is reported as such: a channel named for one company's chief executive appears to be functioning as a catch-all for executive interviews generally, which is precisely the failure the speaker-not-channel rule exists to prevent.

The four claims that remain, in date order:

> 2020-12-19 · neutral · conviction 60 · fact · channel: lex_fridman · no named speaker

> "Abbott's ~99.9% antigen test can be made cheaply; US bought 150M at $5 each ($750M) and Abbott still profited — proof low-cost scale is viable."

> Historical, COVID-era, and now purely explanatory: this is the business that fell from $16.584B to $8.937B. Used as colour only.

> 2021-06-08 · bullish · conviction 85 · thesis · channel: rhonda_patrick · no named speaker · entities include FreeStyle Libre and Abbott

> "Everybody should wear a CGM; reveals glucose spikes and dysregulation invisible to standard HbA1c/fasting tests, even in lean healthy people."

> This is the total-addressable-market expansion argument for the single best asset Abbott owns, made by an independent health-science voice with no position. It is a category claim rather than an equity claim, and it is the strongest demand-side input available.

> 2023-05-10 · bullish · conviction 75 · thesis · channel: business_breakdowns · no named speaker · entities: Dexcom, DXCM, Abbott, ABT, Medtronic, MDT

> "CGM is a stable duopoly of Dexcom and Abbott; competition is not a real risk because manufacturing accurate sensors is very hard."

> The best claim in the lane and the only structural moat statement about Abbott from an independent source. It is a claim about the market structure of Abbott's fastest-growing product, and it is directly testable: new entrants taking share would falsify it.

> 2020-07-09 · neutral · conviction 35 · thesis · speaker: David Sinclair · role: independent · entity: ABT

> "Endorses Abbott's Libre Link, a two-week bluetooth CGM patch, as a useful tool for tracking blood-glucose responses to food."

> A named independent speaker, but a product endorsement rather than an equity view, and at conviction 35 the weakest claim in the file. Used as corroboration of the adoption argument only.

Conclusion, stated as a finding. After removing eight management-voice claims, the Synthos knowledge base has essentially no view on Abbott Laboratories as a security. It has a good independent structural view of continuous glucose monitoring — a duopoly protected by manufacturing difficulty, with a demand curve one independent voice argues extends to the whole population — and that supports the Medical Devices segment specifically. There is not one claim in the knowledge base about the Exact Sciences acquisition, the $20 billion of new debt, or the diagnostics collapse — i.e. nothing about the three facts that actually determine this stock today. Conviction Low, breadth 4.

7. Data integrity — what we rejected from the vendor file and why

Nine findings, and the first is the largest absolute error in this batch.

1. The balance sheet is six months stale and misses a $20.0 billion bond issue and a $20.6 billion acquisition — REJECTED and rebuilt from the 10-Q. The vendor's most recent balance sheet is 2025-12-31 with netDebt of $6,545M. Between that date and 2026-06-30, Abbott issued $20.0 billion of senior notes in March 2026 (eight tranches, coupons 3.700% to 5.600%, maturities 2029 to 2066) and closed the $20.6 billion Exact Sciences acquisition on 2026-03-23. The 10-Q shows long-term debt of $29,603M plus current maturities of $3,005M = $32,608M, against cash of $5,104M and short-term investments of $499M. The vendor reports net debt of $6.545B; the 10-Q supports $27.005B; we use $27.005B — a 313% understatement corrected. Goodwill rose $24,035M → $35,244M, intangibles $5,526M → $17,211M, total assets $86,713M → $109,215M.

2. The vendor file is internally inconsistent by roughly $21 billion. bal_a[0].netDebt says $6,545M, but enterpriseValueTTM of $210.198B against a $182.694B market capitalisation implies $27.504B, and netDebtToEBITDATTM of 2.766x implies the same. The derived trailing metrics reflect the acquisition; the balance sheet does not. The ratio block is right and the balance sheet is wrong, which is the reverse of the usual pattern and is stated because the balance sheet is the field most readers trust. Our rebuilt enterprise value of $210.351B is within 0.07% of the vendor's.

3. seg_geo is corrupt and REJECTED in full. The fiscal-2025 entry contains fields named "C [N]", "D [E]", "I [N]", "J [P]" and "C [H]" — truncated XBRL country tags — plus a Non-US subtotal of $15,979M and UNITED STATES of $17,126M. US plus Non-US sums to $33,105M against reported revenue of $44,328M — 25% of the company is unaccounted for. The same corruption appears in every year back to 2021. No geographic figure appears anywhere in this dive.

4. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED. ebitdaAvg / revenueAvg = 26.76% and ebitAvg / revenueAvg = 19.23% in all eight years, to four significant figures. These are close to Abbott's real figures (fiscal-2025 EBITDA 26.06% of revenue, operating margin 18.2%), which makes them harder to detect and no more usable. All forward valuation runs on epsAvg, which cross-checks to niAvg within 0.4%.

5. The FY2024 income statement contains a $6.389 billion TAX BENEFIT and the reported EPS is not run-rate — flagged, and excluded from all trend work. incomeTaxExpense for fiscal 2024 is minus $6,389M on pre-tax income of $7,013M, producing net income of $13,402M and GAAP diluted EPS of $7.64 — against $3.72 in 2025 and $3.27 in 2023. The effect is concentrated in the fourth quarter, where inc_q shows net income of $9,229M and diluted EPS of $5.27 on revenue of $10,974M and operating income of $1,990M. Any year-on-year GAAP earnings comparison spanning 2024 is meaningless. The extracted 10-K in this archive does not carry the income-tax note, so we can size the item but not attribute it to a disclosed driver, and we say so rather than guessing. No conclusion in this dive uses fiscal-2024 GAAP EPS.

6. Revenue growth is substantially acquired and the payload does not separate it — corrected from the filing. June-quarter revenue of $12,593M (+13.0%) includes $919M of Cancer Diagnostics, the Exact Sciences line created after the 2026-03-23 close. Excluding it, revenue grew roughly 4.8%. The consensus FY2026 revenue figure of $50.309B (+13.5%) is similarly acquisition-inflated. We report organic and reported growth separately at every use.

7. inc_q carries an absurd-precision artefact. The quarter ended 2025-03-31 reports epsdiluted of 0.7583475463879763 — sixteen significant figures for a quantity reported to two decimal places. It is a computed field, not a reported one. We use $0.76 and flag the field as derived rather than sourced.

8. lastDividend: 2.48 is the trailing-twelve-month total — corrected from the filing. The 10-Q shows dividends payable of $1,093M at 2026-06-30 against 1,730,384,021 shares, implying roughly $0.632 per share quarterly and a $2.53 annualised run-rate — a 2.40% yield, not 2.35%.

9. Vendor composite rating — mechanism disclosed. rating gives B+ / 3, with 2 out of 5 on debt-to-equity and price-to-earnings and 3 on price-to-book, against 4s on return on equity, return on assets and discounted cash flow. The debt-to-equity 2 is computed on the STALE balance sheet showing $15.067B of total debt; on the filed $32.608B it would be materially worse. The rating is therefore too generous on the single dimension that has most changed.

Share count — checked and verified exactly clean. The 10-Q balance sheet gives 1,998,291,279 shares issued less 267,907,258 in treasury = 1,730,384,021 outstanding. Market cap of $182,693,876,416 divided by $105.58 gives 1,730,383,000 — agreement to within 0.0001%. No share-class or partial-unit error.

quote.price ($105.58) and tech.last ($105.71) disagree by 0.12%. Every price-derived figure uses quote.price, which reconciles with the market capitalisation and the filed share count; every technical percentage uses the tech block. Stated rather than silently reconciled. quote.yearHigh/yearLow ($137.49 / $81.97) disagree with tech.hi52/lo52 ($136.62 / $82.56) by 0.6% and 0.7%; we use tech. Note that tech.max_dd_from_peak of −25.27% exceeds pct_from_hi of −22.62% because peak is a six-year maximum (implying roughly $141) — per the data contract this is legitimate, not a defect.

An unquantified contingent liability with no vendor field. Note 12 discloses that "Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow's milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC) and inadequately warn". No accrual is visible in the extracted text and no vendor field of any kind captures it. We flag it as an unsized liability rather than estimating one.

Non-equity tripwire — checked and passed. ABT is common stock without par value, NYSE-listed, with 1,000,000 preferred shares authorised and NONE issued. Price $105.58 is not par-like; beta 0.607; the dividend is variable and has a long record of increases; volume 4.92M shares (~$520M of turnover); the 52-week band of $82.56 to $136.62 is a 65% range. This is common equity.

8. Technicals

• Price $105.58. −22.6% from the 52-week high of $136.62; +28.0% above the low of $82.56. Position within the annual range: 42nd percentile.
• Moving averages, split and unusual: +12.3% above a 50-day average of $94.04 but −2.3% BELOW a 200-day of $108.10. The 50-day is far below the 200-day, which is the signature of a downtrend in which a sharp bounce is now testing the longer average from underneath.
• RSI 79.3 — deeply overbought, and by a wide margin the highest reading in this batch (the next is 69.1). MACD +3.81 — positive. A 79 RSI in a stock 22.6% below its high means the bounce has been violent, not that the stock is strong.
• Maximum drawdown from the six-year peak: −25.3%, implying a peak near $141.
• Relative performance, and the two horizons contradict each other: 3-month +20.8% vs SPY +7.6% and QQQ +7.7% — the second-best three-month figure in this batch; 6-month −3.4% vs SPY +11.1%; 12-month −17.0% vs SPY +24.3% and QQQ +30.8% — a forty-one point twelve-month deficit. Abbott had a very bad year and a very good quarter.
• Sentiment: 0 strong buy, 31 buy, 10 hold, 0 sell across 41 analysts. Consensus target $123 (+16.5%), median $120.50, high $145 (+37.3%), low $92 — 12.9% below spot.

Today's move and the entry

ABT closed 2026-08-04 at $105.58, DOWN 1.44% or $1.54 from $107.12, on 4.92M shares. It opened at $106.72 — the day's high — and closed near the low of $104.92. A weak session in a market that rose, and the only decline among the twelve names in this batch on this date. No company-specific news appears in this file for 2026-08-04; the last event was the 2026-07-16 second-quarter release nineteen days earlier.

The honest read: this is the worst technical entry in this batch. RSI 79.3, 12.3% above the 50-day, testing the 200-day from below, after a 20.8% three-month advance, on a down day with a lower close. A stock in that configuration typically consolidates.

What would change the answer:

• A price near $92 — roughly 15.2x FY2027E and the street's own low target — which would put our $115 base at +25% and the bear case level with the price. That is 12.9% below today's close and well inside the range this stock has traversed this year.
• Or a decisive reclaim of the 200-day at $108.10 on the 2026-10-21 print, with Cancer Diagnostics revenue above $1.0 billion. At that point paying 19x is defensible because the acquisition has a second data point.

9. Insiders

The insider file for Abbott contains no material open-market activity in either direction, and we report it as neutral. There are no open-market purchases and no discretionary open-market sales of size. With the stock 22.6% below its 52-week high for most of the last year, the absence of insider buying into that drawdown is a mild negative and no more than that — Abbott's officers are subject to a large, formal equity programme and the file's contents are dominated by its mechanics rather than by decisions.

The more informative governance fact is in the capital allocation, not the Form 4s: the board authorised a $20.6 billion acquisition funded entirely with debt while running a buyback of $893 million — under half a percent of market capitalisation. That is a clear statement of priorities and it is the right one for a company that has just levered up, but it means shareholders' return over the next two years depends on integration rather than on distribution.

10. Verdict, kill-criteria and flip conditions

Watch.

What is genuinely strong: Medical Devices at $21.387 billion and 48.2% of revenue, up 45.6% in three years, anchored by FreeStyle Libre in a market an independent source describes as a duopoly protected by manufacturing difficulty; free cash flow of $7.395 billion on $2.171 billion of capital expenditure; beta of 0.607, the lowest in this batch; a four-segment structure with no segment above half the company and no patent cliff; interest coverage of 12.45x even after the issuance; no preferred stock; a share count verified exactly against the filing; and a base-case asymmetry of 2.52:1, the second-best here.

What we are declining to pay for: net debt that went from $6.545 billion to $27.005 billion in six months, taking leverage from 0.66x to 2.72x EBITDA, on a $20.6 billion acquisition at roughly 5.6x annualised revenue with one quarter of evidence; goodwill and intangibles of $52.455 billion — 48.0% of assets — against a return on invested capital of 6.07% that will now fall; GAAP diluted EPS of $1.15 in the first half against $1.77, with June-quarter operating margin down 420 basis points; roughly $900 million a year of new cash interest, permanent and in both earnings measures; an unsized necrotizing enterocolitis litigation; RSI 79.3 testing the 200-day from below after a 20.8% bounce; a knowledge-base lane that is 73% mis-filed management voice and contains nothing at all about the acquisition, the debt or the diagnostics collapse; and a base fair value of $115 that is 8.9% above spot and 6.5% below the street's $123.

The distinction that matters. Abbott is a good business that has just made the largest and most levered decision in its recent history, and it has reported exactly one quarter under the new structure. We are not saying the deal fails. We are saying that two things happened at once — a fundamental change in the credit and a violent technical bounce — and that neither has been in place long enough to underwrite at 19x with our fair value below consensus. In the Synthos frame that is a Watch by construction, and the wanted price is specific.

Pre-registered KILL criteria — what would take this to Avoid:

• Cancer Diagnostics revenue flat or falling in the 2026-10-21 print against the $919 million June-quarter base. At 5.6x sales the acquired business has to grow.
• A goodwill or intangible impairment against the $22.9 billion of purchase accounting added in March.
• Net debt above $28 billion at year-end, or any further debt-funded acquisition before leverage returns below 2x.
• Medical Devices growth below 8%. It is the only organically compounding segment and 48.2% of revenue.
• A quantified necrotizing enterocolitis accrual above roughly $2 billion, which the filings currently do not size at all.

Pre-registered FLIP conditions — what would take this to Buy — Tactical:

• Price at or below approximately $92 (roughly 15.2x FY2027E, and the street's own low target) with the business intact. This is the most likely path to a Buy and it is 12.9% below today's close. At $92 the base case is +25% and the bear case is at the price.
• Cancer Diagnostics above $1.0 billion in the September quarter with a disclosed segment margin — the second data point that turns an acquisition into a franchise.
• Net debt below $25 billion by the fourth quarter, demonstrating that free cash flow is deleveraging on schedule.
• A decisive reclaim of the 200-day average at $108.10 with RSI back below 65, which would convert a bounce into a trend.
• Genuine independent knowledge-base conviction appearing. Eight of eleven current claims are management voice; a single independent claim about the acquisition or the post-COVID diagnostics franchise would be worth roughly one tier.

Where ABT fits in the Synthos Framework Portfolio. The medical-technology and diagnostics sleeve, at 0% today with a 1.5-2% target on a fill near $92 or a confirmed Cancer Diagnostics ramp. On batch overlap: ABT and GILD are the two healthcare names here and they are not the same exposure — Abbott is a device and diagnostics group with no patent cliff and a leveraged balance sheet; Gilead is a therapeutics franchise with the opposite profile. Holding both is defensible. Abbott's 0.607 beta makes it the natural defensive holding in this batch alongside LIN and UNP. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $105.58.

Single biggest risk: the Exact Sciences acquisition. $20.6 billion of purchase price, funded with $20.0 billion of debt at coupons to 5.600% maturing as far out as 2066, against $919 million of first-full-quarter revenue — roughly 5.6x annualised sales. It took net debt from $6.545 billion to $27.005 billion, leverage from 0.66x to 2.72x, and goodwill and intangibles from $29.561 billion to $52.455 billion on a company whose return on invested capital was 6.07% before the deal. There is one quarter of evidence. If Cancer Diagnostics does not compound, Abbott has converted a fortress balance sheet into a moderately levered one in exchange for revenue that replaces what COVID testing took away without adding to it — and at 19.1x forward, the price does not contain that outcome.

Most fragile assumption in the price: that adjusted EPS of $6.722 in fiscal 2028 is the right measure to pay for. The adjusted series excludes the acquisition amortisation that is currently halving GAAP earnings, and that exclusion is defensible for non-cash items. But roughly $900 million a year of new cash interest is not excluded, is permanent, and is roughly 7% of the FY2027 consensus. The FY2028 consensus range of $4.496 to $8.060 — a 1.79x spread on ten analysts — is the market's own admission that nobody yet knows what this company earns. If FY2028 adjusted EPS lands at $5.50 rather than $6.72, then at 19x the stock is $105 — today's price, two and a half years from now.

Provenance & disclosures

• Traceability: 14 raw knowledge-base hits (11 entity, 3 text); 4 used; 10 discarded. The central finding: EIGHT of the eleven entity claims are dated 2020-01-23, come from a single channel slug named for the chief executive of an unrelated pharmaceutical company, and are unmistakably ABBOTT MANAGEMENT VOICE — they recite fiscal-2020 per-share guidance ($3.55-$3.65 adjusted EPS, Q1 $0.69-$0.71, ~59% gross margin), describe 'our four businesses', and walk through Alinity, MitraClip, TriClip, Tendyne, Portico and Established Pharmaceuticals product by product. No independent analyst issues next-quarter per-share guidance ranges. All eight are excluded from the conviction pool, quoted at half weight, and are additionally six and a half years stale. The same channel slug carries IBM's chief executive elsewhere in this batch, which makes this a SYSTEMIC mis-filing rather than a single error and is reported as such. Of the four claims used, one carries a named independent speaker (David Sinclair, 2020-07-09, a Libre product endorsement at conviction 35) and three are channel-attributed with no named speaker. The most valuable is the 2023-05-10 structural claim that continuous glucose monitoring is 'a stable duopoly of Dexcom and Abbott' because 'manufacturing accurate sensors is very hard' — the only independent moat statement about Abbott in the file. There is not one claim in the entire knowledge base about the Exact Sciences acquisition, the $20 billion of new debt, or the diagnostics collapse — the three facts that determine this stock today, and we state that absence rather than padding around it. Net conviction positive-low, breadth 4. Searches: Abbott, Libre, Exact Sciences, Cologuard. All quotes are verbatim from the stored claim text.
• Data as-of: fundamentals — annual statements to 2025-12-31 from the vendor payload; quarterly income statement to 2026-06-30; most recent filing-verified financials 2026-06-30, from the 10-Q filed 2026-07-28 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873515 = 2026-08-04T19:58:35Z ($105.58, −1.44%; 50-DMA $94.04; 200-DMA $108.10; RSI 79.3; MACD +3.81) · knowledge-base claims 2026-08-04. Fiscal note: Abbott's fiscal year is the calendar year. All figures come from the Synthos vendor data file for ABT or from the SEC filings in the ABT archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-20 (fiscal 2025); 10-Q filed 2026-04-29 (March 2026 quarter); 10-Q filed 2026-07-28 (June 2026 quarter); 8-K filed 2026-04-17; 8-K filed 2026-04-27; 8-K filed 2026-07-16 (second-quarter results). All six carry preserved financial tables (tables: true), which is why the balance sheet, debt schedule, segment table and acquisition disclosure in this dive are filing-sourced. One gap: the extracted 10-K covers the risk factors and much of the narrative but not the income-tax note, so the fiscal-2024 tax benefit of $6.389 billion can be sized from the statements but not attributed to a disclosed driver — stated rather than guessed.
• Where the filings contradicted or corrected the vendor (detailed in Section 7): net debt rebuilt from the vendor balance sheet's $6,545M to $27,005M — a 313% understatement, because the payload's most recent balance sheet (2025-12-31) predates the $20.0 billion senior-note issuance of March 2026 (eight tranches, 3.700% to 5.600%, 2029 to 2066) and the $20.6 billion Exact Sciences acquisition completed 2026-03-23, with the 10-Q showing long-term debt of $29,603M plus current maturities of $3,005M against cash of $5,104M and short-term investments of $499M; goodwill ($24,035M → $35,244M), intangibles ($5,526M → $17,211M) and total assets ($86,713M → $109,215M) all taken from the 10-Q; the vendor file shown to be internally inconsistent by roughly $21 billion, since enterpriseValueTTM of $210.198B and netDebtToEBITDATTM of 2.766x both DO reflect the financing while bal_a[0].netDebt does not; seg_geo rejected in full for containing truncated XBRL tags ("C [N]", "D [E]", "I [N]", "J [P]", "C [H]") and failing to account for 25% of revenue ($33,105M of named lines against $44,328M reported); est.ebitdaAvg/ebitAvg rejected on a fixed-ratio fabrication signature (26.76% and 19.23% of revenue in all eight years); the fiscal-2024 $6,389M tax BENEFIT identified and all fiscal-2024 GAAP comparisons excluded; revenue growth separated into organic and acquired using the filing's $919M Cancer Diagnostics line (June-quarter growth +13.0% reported, roughly +4.8% organic); an absurd-precision epsdiluted artefact (0.7583475463879763) flagged as a derived rather than reported field; and lastDividend of $2.48 identified as the TTM total against a filing-implied $2.53 forward run-rate derived from $1,093M of dividends payable. Where vendor and filing AGREED — worth recording: the share count (10-Q's 1,998,291,279 issued less 267,907,258 treasury = 1,730,384,021, matching the implied market-cap count to 0.0001%); seg_prod summing to reported revenue within 0.04%; the enterprise value within 0.07%; and the quarterly revenue and adjusted-EPS series against the earnings calendar.
• Basis note: analyst estimates in est.epsAvg are adjusted (non-GAAP) EPS — verified because the fiscal-2025 row of $5.152 matches the sum of the earn_cal quarterly actuals and does NOT match GAAP diluted EPS of $3.72. The GAAP-to-adjusted gap is 69% on the trailing twelve months ($3.11 GAAP against $5.26 adjusted) and it is WIDENING, because $22.9 billion of newly recognised goodwill and intangibles will amortise for years. Forward multiples in this dive use consensus adjusted EPS, and the trailing multiple is shown on both bases (20.1x adjusted, 33.9x GAAP). The adjusted measure correctly excludes non-cash amortisation but does NOT exclude roughly $900 million a year of new cash interest, which is permanent and in both measures.
• Estimate coverage: 17 analysts on FY2026 EPS and 20 on revenue; 17 and 20 on FY2027; 10 and 20 on FY2028; 4 and 11 on FY2029; 4 and 11 on FY2030 — FY2029 and FY2030 are excluded. The FY2028 EPS range of $4.496 to $8.060 — a 1.79x spread on 10 analysts, against FY2026's 1.3% spread on 17 — is disclosed at every point of use and is why the FY2027 line anchors the base case.
• Peer note: the vendor peer set mixes device, pharmaceutical and managed-care companies. UnitedHealth ($370.9B), Merck ($317.3B), Novartis ($291.3B), Novo Nordisk ($196.6B) and Thermo Fisher ($209.6B) are not business-model comparables; the defensible device peers are Medtronic ($110.1B), Stryker ($128.9B), Boston Scientific ($73.0B) and Intuitive Surgical ($130.0B). Dexcom — the other half of the continuous-glucose-monitoring duopoly the knowledge base identifies — is NOT in the payload. GILD, also covered in this batch, appears in Abbott's peer set and is not a comparable; the two dives should not be read against each other on multiples. No peer multiples are supplied, so no peer-multiple comparison is drawn.
• Fair-value caveat: the $90 / $115 / $145 anchors are multiples of the fiscal-2027 and fiscal-2028 consensus adjusted-EPS distributions — 15x the FY2027 low of $6.003, 19x the FY2027 mean of $6.063 (17 analysts), and 18x the FY2028 high of $8.060 (10 analysts). Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 17x FY2027E gives $103, 2.4% BELOW spot; 21x gives $127. The whole answer lives in a 17-21x band. Both tails are corroborated by the published target distribution — our bear of $90 sits 2.2% below the street's $92 low and our bull of $145 is exactly the street's $145 high.
• Timing: second-quarter 2026 results were released 2026-07-16, nineteen days before this dive, beating adjusted EPS by three cents ($1.31 against $1.28) while GAAP diluted EPS fell to $0.53 from $1.01. The next print is 2026-10-21, 78 days away, and it is the first full-quarter read on the Exact Sciences integration. 2026-08-04 was a firm broad market and ABT fell 1.44% — the only decline among the twelve names in this batch on this date — opening at the day's high and closing near the low.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.